BiondVax Pharmaceuticals Performance
| BVXVDelisted Stock | USD 1.35 0.03 2.17% |
The firm shows a Beta (market volatility) of -0.13, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning BiondVax Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, BiondVax Pharmaceuticals is likely to outperform the market. BiondVax Pharmaceuticals right now shows a risk of 0.0%. Please confirm BiondVax Pharmaceuticals jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if BiondVax Pharmaceuticals will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days BiondVax Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, BiondVax Pharmaceuticals is not utilizing all of its potentials. The recent stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
| Begin Period Cash Flow | 17.5 M |
BiondVax |
BiondVax Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 135.00 in BiondVax Pharmaceuticals on September 29, 2024 and sell it today you would earn a total of 0.00 from holding BiondVax Pharmaceuticals or generate 0.0% return on investment over 90 days. BiondVax Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than BiondVax, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BiondVax Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BiondVax Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BiondVax Pharmaceuticals, and traders can use it to determine the average amount a BiondVax Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| BVXV |
Based on monthly moving average BiondVax Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BiondVax Pharmaceuticals by adding BiondVax Pharmaceuticals to a well-diversified portfolio.
BiondVax Pharmaceuticals Fundamentals Growth
BiondVax Stock prices reflect investors' perceptions of the future prospects and financial health of BiondVax Pharmaceuticals, and BiondVax Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BiondVax Stock performance.
| Return On Equity | -56.02 | |||
| Return On Asset | -0.31 | |||
| Current Valuation | 21.94 M | |||
| Shares Outstanding | 3.65 M | |||
| Price To Earning | (4.91) X | |||
| Price To Book | 7.48 X | |||
| EBITDA | (10.5 M) | |||
| Cash And Equivalents | 14.55 M | |||
| Cash Per Share | 2.23 X | |||
| Total Debt | 21.54 M | |||
| Book Value Per Share | (1.96) X | |||
| Cash Flow From Operations | (7.26 M) | |||
| Earnings Per Share | (2.35) X | |||
| Total Asset | 27.07 M | |||
| Retained Earnings | (115.83 M) | |||
| Current Asset | 36.93 M | |||
| Current Liabilities | 1.7 M | |||
About BiondVax Pharmaceuticals Performance
Evaluating BiondVax Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if BiondVax Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BiondVax Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel. Biondvax Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 15 people.Things to note about BiondVax Pharmaceuticals performance evaluation
Checking the ongoing alerts about BiondVax Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BiondVax Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BiondVax Pharmaceuticals is not yet fully synchronised with the market data | |
| BiondVax Pharmaceuticals may become a speculative penny stock | |
| BiondVax Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (5.8 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| BiondVax Pharmaceuticals currently holds about 14.55 M in cash with (7.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.23, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 20.0% of the company shares are held by company insiders |
- Analyzing BiondVax Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BiondVax Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining BiondVax Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BiondVax Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of BiondVax Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BiondVax Pharmaceuticals' stock. These opinions can provide insight into BiondVax Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Other Consideration for investing in BiondVax Stock
If you are still planning to invest in BiondVax Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BiondVax Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |